|
Date
of Report
(Date
of earliestevent
reported):
|
|
May
8, 2007
|
|
|
|
|
|
California
(State
or other
jurisdiction
of
incorporation)
|
|
000-32141
(Commission
File
Number)
|
|
91-2021600
(IRS
Employer
Identification
No.)
|
|
|
|
o
|
|
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
|
|
o
|
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
|
o
|
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
|
|
o
|
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
|
Item 5.02. Departure
of Directors or Principal Officers; Election of Directors; Appointment
of
Principal Officers.
|
|
|
|
|
|
|
NUTRA
PHARMA CORP.
|
|
||
Date:
May 9, 2007
|
/s/
Rik J. Deitsch
|
|
||
|
Rik
J. Deitsch
|
|
||
|
President,
Chief Executive Officer
|
|